U.S. Markets closed

Biocon Limited (BIOCON.NS)

NSE - NSE Real Time Price. Currency in INR
Add to watchlist
390.65-8.65 (-2.17%)
At close: 3:29PM IST
Full screen
Previous Close399.30
Open372.00
Bid0.00 x
Ask390.65 x
Day's Range371.20 - 394.00
52 Week Range268.13 - 438.85
Volume4,724,394
Avg. Volume3,496,325
Market Cap230.14B
BetaN/A
PE Ratio (TTM)37.84
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est352.94
  • FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon's Proposed Biosimilar Trastuzumab
    PR Newswire16 days ago

    FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon's Proposed Biosimilar Trastuzumab

    HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, July 13, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of the companies' proposed biosimilar trastuzumab. The committee voted 16-0 in support of eligible indications of the reference product, Herceptin®, which include HER2-positive breast cancer in the metastatic and adjuvant settings.

  • Reuters2 months ago

    FDA rejects Coherus's biosimilar for Neulasta, shares plunge

    Coherus BioSciences Inc said on Monday the U.S. Food and Drug Administration (FDA) declined to approve its biosimilar copy of Amgen Inc's blockbuster treatment, Neulasta, which is used to fight infections in cancer patients. Shares of Coherus tumbled 30 percent to $14.47 in morning trading, while Amgen's shares were up slightly at $164.19.

  • PR Newswire2 months ago

    Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association's 77th Scientific Sessions

    HERTFORDSHIRE, England and PITTSBURGH and BENGALURU, India, June 10, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced the presentation of new data from the insulin glargine clinical program, including the INSTRIDE studies at the American Diabetes Association's 77th Scientific Sessions in San Diego. The studies confirmed the efficacy, safety and immunogenicity of MYL-1501D, insulin glargine, in comparison to Lantus® in patients with Type 1 and Type 2 diabetes.